Study highlights the FDA’s speed in approving cancer drugs as a new commish looks to rev up reviews
During his confirmation hearing on Wednesday Scott Gottlieb emphasized that he would start his new job as FDA commissioner by focusing on different parts of the agency that have lagged in accelerating drug reviews. With the president beating the table for a streamlined approval process, you can expect some fresh pressure from the top to speed things up. And now Gottlieb — who was already on record on that score — has some additional data to point to for his efficiency campaign, highlighting where the agency has been effective in speeding approvals and where it might push for faster action.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.